Lionel Apetoh
  • E-mail :[email]
  • Phone : +1 317 278 95 18
  • Location : Indianapolis, United States
Last update 2023-02-04 05:13:13.68

Lionel Apetoh PhD Immunology

Course and current status


  • 2023 -   Christopher Brown Professor of Immunology, Indiana University, Indianapolis, United States.

Research focus: “Regulation of T cell differentiation in cancer”


  • 2021-2022 Full Professor of Immunology, University of Tours, France.
  • 2021-2022 Group leader, INSERM, Tours, France.
  • 2017-2021 Associate Professor of Immunology, INSERM, Dijon, France.
  • 2012-2017 Assistant Professor of Immunology, INSERM, Dijon, France.
  • 2010-2021 Group leader, INSERM, Dijon, France.

Research focus: “CD4 T cell differentiation and cancer”

  • 2008-2010 Postdoctoral research fellow at the Brigham and Womens’ Hospital, Harvard Medical School, Boston, MA, United States

Research project: “Transcriptional regulation of CD4 type 1 regulatory T cells”

Supervisor: Pr Vijay Kuchroo 

  • 2004-2008  PhD in immunology (summa cum laude) defended June 3rd 2008 in Villejuif, France. 

Research project: “Immunogenicity of tumor cell death triggered by anticancer therapies”

PhD Supervisor: Pr Laurence Zitvogel


2017 “Platet-Mathieu Prize” (Académie des sciences, belles-lettres et arts de Lyon)

2015 ERC Starting Grant

2015 “Albert Sézary Prize” (French National Academy of Medicine)

2015 “Olga Sain Prize” (Ligue contre le Cancer)

Scientific summary

Our group currently investigates the relationships between CD4 T lymphocytes and anticancer immune responses.

Selected publications (out of more than 120):

  • Benoit-Lizon I, Jacquin E, Rivera Vargas T, Richard C, Roussey A, Dal Zuffo L, Martin T, Mélis A, Vinokurova D, Shahoei SH, Baeza Garcia A, Pignol C, Gioguitti S, Carapito R, Boidot R, Végran F, Flavell RA, Ryffel B, Nelson ER, Soulas-Spaurel P, Lawrence T, Apetoh L 

CD4 T cell-intrinsic STING signaling controls the differentiation and effector functions of Th1 and Th9 cells. J Immunother Cancer, 2022 Jan;10(1):e003459.

  • Dosset M, Rivera Vargas T, Lagrange A, Boidot R, Végran F, Roussey A, Chalmin F, Dondaine L, Paul C, Marie-Joseph EL, Martin F, Ryffel B, Borg C, Adotévi O, Ghiringhelli F, Apetoh L 

PD-1/PD-L1 pathway: an adaptive immune resistance mechanism to immunogenic chemotherapy in colorectal cancer. Oncoimmunology, 2018 Mar 15;7(6):e1433981.

  • Rivera Vargas T, Cai Z, Shen Y, Dosset M, Benoit-Lizon I, Martin T, Roussey A, Flavell RA, Ghiringhelli F, Apetoh L

Selective   degradation    of   the   PU.1   transcription    factor   during   autophagy   represses differentiation and antitumor activity of Th9 cells. Nat. Commun., 2017 Sep 15;8(1):559.

  • Vegran F, Berger H, Boidot R, Mignot G, Bruchard M, Dosset M, Chalmin F, Rébé C, Dérangère V, Ryffel B, Kato M, Prévost-Blondel A, Ghiringhelli F, Apetoh L 

IRF1 dictates the IL-21-dependent anticancer functions of Th9 cells. Nat. Immunol., 2014 Aug;15(8):758-66.

  • Berger H, Végran F, Chikh M, Gilardi F, Ladoire S, Bugaut H, Mignot G, Chalmin F, Bruchard M, Derangère V, Chevriaux A, Rébé C, Pot C, Ryffel B, Hichami A, Desvergnes B, Ghiringhelli F, Apetoh L

SOCS3 transactivation by PPARg prevents IL-17-driven cancer growth. Cancer Res. , 2013 Jun 15;73(12):3578-90.

  • Bruchard M, Mignot G, Derangère V, Chalmin F, Chevriaux A, Végran F, Boireau W, Simon B, Ryffel B, Connat JL, Kanellopoulos J, Martin F, Rébé C, Apetoh L*, Ghiringhelli F*

Chemotherapy-triggered cathepsin B release in myeloid-derived suppressor cells activates the NLRP3 inflammasome and promotes tumor growth. Nat. Med., 2013 Jan;19(1):57-64.* Contributed equally

  • Sakuishi K*, Apetoh L*, Sullivan JM, Blazar BR, Kuchroo VK, Anderson AC 

Targeting Tim-3 and PD-1 pathways to reverse T cell exhaustion and restore anti-tumor immunity. J. Exp. Med. 2010 Sep 27;207(10):2187-94. *Contributed equally 

  • Apetoh L, Quintana FJ, Pot C, Joller N, Xiao S, Kumar D, Burns EJ, Sherr DH, Weiner HL, Kuchroo VK 

The aryl hydrocarbon receptor interacts with c-Maf to promote the differentiation of type 1 regulatory T cells induced by IL-27. Nat. Immunol. 2010 Sep;11(9):854-61.

  • Apetoh L, Ghiringhelli F, Tesniere A, Obeid M, Ortiz C, Criollo A, Mignot G, Maiuri MC, Ullrich E, Saulnier P, Yang H, Amigorena S, Ryffel B, Barrat FJ, Saftig P, Levi F, Lidereau R, Nogues C, Mira JP, Chompret A, Joulin V, Clavel-Chapelon F, Bourhis J, André F, Delaloge S, Tursz T, Kroemer G and Zitvogel L

Toll-like Receptor 4-dependent contribution of the immune system to anticancer chemotherapy and radiotherapy. Nat. Med. 2007 Sep:13(9):1050-1059.

Image d’exemple